Bimekizumab Led to Rapid and Deep Normalization of Molecular Signatures Associated with PASI Sub-Components, Preceding Clinical Skin Clearance

The study investigated the effects of bimekizumab (BKZ) on psoriatic skin, focusing on the Psoriasis Area and Severity Index (PASI) sub-components: erythema, thickness, and scaling. In the BE RADIANT trial, patients receiving BKZ showed significant reductions in these sub-scores by Week 8, with ≥95% improvement by Week 12, maintained through Week 48. Molecular analysis revealed complete normalization of gene signatures associated with these sub-components by Week 8. The study found a correlation between changes in interleukin (IL)17A/IL17F expression and gene expression changes, highlighting BKZ's impact on keratinocytes. The results demonstrate that molecular resolution precedes clinical skin clearance, with all sub-components being reliable indicators of BKZ response.